Chilton Capital Management
RIGL icon

Chilton Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Chilton Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-47
Closed -$2.01K – 728
2025
Q4 		$2.01K Buy
+47
New +$1.77K ﹤0.01% 540

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Chilton Capital Management's RIGL Position: Q1 2026 in Review

Chilton Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 47 shares — an estimated $2.01K sold.

Chilton Capital Management first reported a position in RIGL in Q4 2025 and held it in 1 quarter. The position peaked at $2.01K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Chilton Capital Management reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Chilton Capital Management sold 47 Rigel Pharmaceuticals shares in Q1 2026, an estimated $2.01K.
  • Chilton Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Chilton Capital Management's Rigel Pharmaceuticals position peaked at $2.01K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Chilton Capital Management's 13F filing for Q1 2026, filed 11 May 2026.